Company

Newron Pharmaceuticals SpA

Headquarters: Bresso, MI, Italy

Employees: 23

XETR: NP5 +1.70%

Market Cap

€155.0 Million

EUR as of July 1, 2024

US$166.5 Million

Market Cap History

Newron Pharmaceuticals SpA market capitalization over time

Evolution of Newron Pharmaceuticals SpA market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Newron Pharmaceuticals SpA

Detailed Description

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its product pipeline comprises Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Newron Pharmaceuticals SpA has the following listings and related stock indices.


Stock: XETR: NP5 wb_incandescent

Stock: FSX: NP5 wb_incandescent

Stock: OTC: NWPHF wb_incandescent

Details

Headquarters:

Via Antonio Meucci 3

Bresso, MI 20091

Italy

Phone: 39 026 103461

Fax: 39 02 61 03 46 54